Liu Xiaoqiang, Lazzaroni Caterina, Aly Sherine A, Thungrat Kamoltip, Boothe Dawn M
College of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi 712100, PR China.
Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
Vet Microbiol. 2014 Dec 5;174(3-4):514-522. doi: 10.1016/j.vetmic.2014.10.011. Epub 2014 Oct 25.
This study explored and compared the mechanisms and selective concentration of resistance between a 3rd (pradofloxacin) and 2nd (ciprofloxacin) generation fluoroquinolone. Pradofloxacin- and ciprofloxacin-resistant mutants were selected by stepwise exposure of Escherichia coli (E. coli) to escalating concentrations of pradofloxacin and ciprofloxacin. The sequence of the quinolone resistance determining region (QRDR) and the transcriptional regulator soxS were analyzed, and efflux pump AcrAB-TolC activity was measured by quantitative real-time reverse transcription-PCR (qRT-PCR). First-step mutants reduced the fluoroquinolone sensitivity and one mutant bore a single substitution in gyrA. Four of six second-step mutants expressed ciprofloxacin resistance, and displayed additional mutations in gyrA and/or parC, while these mutants retained susceptibility to pradofloxacin. All the third-step mutants were fluoroquinolone resistant, and each expressed multidrug resistance (MDR) phenotypes. Further, they displayed resistance to all antibacterials tested except cefotaxime, ceftazidime and meropenem. The number of mutations in QRDR of gyrA and parC correlated with fluoroquinolone MICs. Mutations in parC were not common in pradofloxacin-associated mutants. Moreover, one second- and one third-step ciprofloxacin-associated mutants bore both mutations at position 12 (Ala12Ser) and 78 (Met78Leu) in the soxS gene, yet no mutations in the soxS gene were detected in the pradofloxacin-selected mutants. Altogether, these results demonstrated that resistance emerged relatively more rapidly in 2nd compared to 3rd generation fluoroquinolones. Point mutations in gyrA were a key mechanism of resistance to pradofloxacin, and overexpression of efflux pump gene acrB played a potential role in the emergence of MDR phenotypes identified in this study.
本研究探讨并比较了第三代(普拉氟沙星)和第二代(环丙沙星)氟喹诺酮类药物的耐药机制及选择性浓度。通过将大肠杆菌逐步暴露于浓度递增的普拉氟沙星和环丙沙星中,筛选出对普拉氟沙星和环丙沙星耐药的突变体。分析喹诺酮耐药决定区(QRDR)的序列和转录调节因子soxS,并通过定量实时逆转录PCR(qRT-PCR)测定外排泵AcrAB-TolC的活性。第一步突变体降低了氟喹诺酮敏感性,其中一个突变体在gyrA中发生了单个取代。六个第二步突变体中有四个表现出对环丙沙星的耐药性,并在gyrA和/或parC中出现了额外的突变,而这些突变体对普拉氟沙星仍敏感。所有第三步突变体均对氟喹诺酮耐药,且均表现出多药耐药(MDR)表型。此外,它们对除头孢噻肟、头孢他啶和美罗培南之外的所有测试抗菌药物均耐药。gyrA和parC的QRDR中的突变数量与氟喹诺酮最低抑菌浓度(MIC)相关。parC中的突变在与普拉氟沙星相关的突变体中并不常见。此外,一个与环丙沙星相关的第二步和第三步突变体在soxS基因的第12位(Ala12Ser)和第78位(Met78Leu)均发生了突变,但在普拉氟沙星选择的突变体中未检测到soxS基因的突变。总之,这些结果表明,与第三代氟喹诺酮相比,第二代氟喹诺酮耐药性出现得相对更快。gyrA中的点突变是对普拉氟沙星耐药的关键机制,外排泵基因acrB的过表达在本研究中鉴定出的MDR表型的出现中发挥了潜在作用。